The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
暂无分享，去创建一个
P. Janský | R. Sandhu | C. Granger | L. Wallentin | R. Lopes | J. Alexander | Z. Hijazi | M. Hanna | S. Halvorsen | J. Ezekowitz | U. Andersson